Stevanato Group S.p.A. (STVN)

Market Cap	4.91B
Revenue (ttm)	1.18B
Net Income (ttm)	148.02M
Shares Out	272.77M
EPS (ttm)	0.55
PE Ratio	32.83
Forward PE	32.47
Dividend	$0.06 (0.32%)
Ex-Dividend Date	Jun 4, 2024

Volume	513,106
Open	18.57
Previous Close	18.73
Day's Range	17.78 - 18.57
52-Week Range	16.56 - 36.30
Beta	0.61
Analysts	Buy
Price Target	34.17 (+89.83%)
Earnings Date	Jul 26, 2024

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,634
• Stock Exchange: NYSE
• Ticker Symbol: STVN

Financial Performance

In 2023, STVN's revenue was 1.09 billion, an increase of 10.34% compared to the previous year's 983.68 million. Earnings were 145.63 million, an increase of 1.95%.

Financial numbers in EUR

Analyst Forecast

According to 6 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $34.17, which is an increase of 89.83% from the latest price.

Price Target

$34.17

(89.83% upside)

Analyst Consensus: Buy